PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials

被引：0
|
作者：
Papp, Kim [1 ,2 ]
Vender, Ronald [3 ]
Langley, Richard [4 ]
Ho, Vincent [5 ]
Park-Wyllie, Laura [6 ]
Abbarin, Nastaran [6 ]
Miller, Megan [7 ]
You, Yin [7 ]
Yang, Ya-Wen [8 ]
机构：
[1] Probity Med Res Inc, Waterloo, ON, Canada
[2] K Papp Clin Res, Waterloo, ON, Canada
[3] McMaster Univ, Div Dermatol, Dept Med, Hamilton, ON, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[6] Janssen Inc, Janssen Med Affairs, Toronto, ON, Canada
[7] Janssen Res & Dev LLC, Spring House, PA USA
[8] Janssen Pharmaceut Companies Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB203 / AB203
页数：1
相关论文
共 50 条
  • [41] Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: Results through week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrea
    Tyring, Stephen
    Philipp, Sandra
    Adam, David
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB267 - AB267
  • [42] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    Armstrong, April W.
    Reich, Kristian
    Foley, Peter
    Han, Chenglong
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Papp, Kim A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (01) : 155 - 164
  • [43] Improvement in absolute psoriasis area and severity index score through 3 years of continuous treatment with guselkumab in VOYAGE 1
    Puig, L.
    Gordon, K. B.
    Tsai, T. -F.
    Thaci, D.
    Gooderham, M.
    Fakharzadeh, S.
    Li, S.
    Shen, Y. -K.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 108 - 108
  • [44] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    April W. Armstrong
    Kristian Reich
    Peter Foley
    Chenglong Han
    Michael Song
    Yaung-Kaung Shen
    Yin You
    Kim A. Papp
    American Journal of Clinical Dermatology, 2019, 20 : 155 - 164
  • [45] Maintenance of response through up to 3-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial
    Reich, K.
    Song, M.
    Randazzo, B.
    Fakharzadeh, S.
    Li, S.
    Shen, Y. -K.
    Han, C.
    Armstrong, A.
    Foley, P.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 31 - 32
  • [46] Improvement in absolute psoriasis area and severity index score through 3 years of continuous treatment with guselkumab in the VOYAGE 1 trial
    Puig, L.
    Gordon, K. B.
    Tsai, T. -F.
    Thaci, D.
    Gooderham, M.
    Fakharzadeh, S.
    Li, S.
    Shen, Y. -K.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 47 - 47
  • [47] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasis
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42
  • [48] Maintenance of response through up to 3-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial
    Reich, Kristian
    Song, Michael
    Randazzo, Bruce
    Li, Shu
    Shen, Yaung-Kaung
    Han, Chenglong
    Armstrong, April
    Foley, Peter
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB236 - AB236
  • [49] Improvement in absolute Psoriasis Area and Severity Index score through 3 years of continuous treatment with guselkumab in the VOYAGE 1 trial
    Puig, Luis
    Gordon, Kenneth B.
    Tsai, Tsen-Fang
    Thaci, Diamant
    Gooderham, Melinda
    Fakharzadeh, Steven
    Li, Shu
    Shen, Yaung-Kaung
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB224 - AB224
  • [50] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatment: Voyage 1&2 trials
    Puig, L.
    Tsai, T.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 81 - 81
12345